Wednesday, April 08, 2020 3:19:02 PM
In the filings you will see that this first in human trial does not involve the human instrument, it is only a test of the nanoparticles. If successful, then and only then will they complete the design and development of the human instrument (which will need a lot more cash and dilution). I know this conflicts with all the bs posted by rustydog, but read for yourself. The clinical version of a human instrument is still just a concept. The filings make it clear.
Also, price not moving because they need all the cash they have, all the cash they can raise from the latest announced round of dilution and all the cash from tax loss forgiveness to get through the first trial.
Don't take my word for it, and for sure don't believe the "moonshot" narrative and bogus due diligence. Take the time and read through ibx filings and you can get the truth right from the source.
Recent MHTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 07:12:38 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 07:44:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:04:24 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM